Prurigo Nodularis clinical trials at UCLA

1 research study open to eligible people

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
open to eligible people ages 18 years and up
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Santa Monica, California and other locations

Last updated: May 28, 2026